EpiCept to Host Second Quarter 2007 Conference Call and Webcast on August 14,
2007
TARRYTOWN, N.Y., Aug. 9 /PRNewswire/ --
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that
it will host a conference call to discuss second quarter 2007 results and
provide a business update on Tuesday, August 14, 2007 at 8:30 a.m. EDT. EpiCept
will release results for the three and six months ended June 30, 2007 after the
close of the market on Monday, August 13, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
To participate in the live call, please dial (888) 802-7346 from the U.S. or
Canada or (973) 582-2785 from international locations (please reference access
code 9106229). The conference call will also be broadcast live on the Internet
and may be accessed at www.epicept.com. The web cast will be archived for 90
days.
A telephone replay of the call will be available for seven days by dialing (877)
519-4471 from the U.S. and Canada or (973) 341-3080 from international locations
(please reference reservation number 9106229).
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept
has a staged portfolio of pharmaceutical product candidates with several pain
therapies in late-stage clinical trials, and a lead oncology compound (for acute
myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a
marketing authorization application for this compound has been submitted in
Europe. EpiCept is based in Tarrytown, N.Y., and its research and development
team in San Diego is pursuing a drug discovery program focused on novel
approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that Ceplene will not receive regulatory approval or marketing
authorization in the EU or, if approved, will not achieve significant commercial
success, the risk that Myriad's development of Azixa will not be successful, the
risk that Azixa will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant payments
under our agreement with Myriad, the risk that the development of our other
apoptosis product candidates will not be successful, the risk that our ASAP
technology will not yield any successful product candidates, the risk that
clinical trials for NP-1 will not be successful, that NP-1 will not receive
regulatory approval or achieve significant commercial success, the risk that our
other product candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or later stage
clinical trials, the risk that EpiCept will not obtain approval to market any of
its product candidates, the risks associated with reliance on additional outside
financing to meet its capital requirements, the risks associated with dependence
upon key personnel, the risks associated with reliance on collaborative partners
and others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and uncertainties
associated with our scientific research, product development, clinical trials
and regulatory approval process; our history of operating losses since our
inception; competition; litigation; risks associated with prior material
weaknesses in our internal controls; and risks associated with our ability to
protect our intellectual property. These factors and other material risks are
more fully discussed in EpiCept's periodic reports, including its reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in EpiCept's filings which are available at www.sec.gov or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions, unknown
risks or uncertainties or other risk factors.
EPCT-GEN
SOURCE EpiCept Corporation
-0- 08/09/2007
/CONTACT: Robert W. Cook, EpiCept Corporation, +1-914-606-3500,
rcook@epicept.com; Greg Kelley, Feinstein Kean Healthcare, +1-617-577-8110,
gregory.kelley@fkhealth.com; Kim Sutton Golodetz, +1-212-838-3777,
kgolodetz@lhai.com, or Bruce Voss, +1-310-691-7100 bvoss@lhai.com, both of
Lippert/Heilshorn & Associates /
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO
PRN Photo Desk, photodesk@prnewswire.com /
/Web site: http://www.epicept.com /
(EPCT)
EpiCept to Host Second Quarter 2007 Conference Call and Webcast on August 14, 2007
| Source: Immune Pharmaceuticals Inc
Attachments
